Source: StreetInsider

Press Release: Verastem : Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc.�(Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 112,000 shares of its common stock to four new employees.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Brian Stuglik's photo - CEO of Verastem

CEO

Brian Stuglik

CEO Approval Rating

66/100

Verastem is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of cancer. Read more